CY1110781T1 - Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης - Google Patents

Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης

Info

Publication number
CY1110781T1
CY1110781T1 CY20101100748T CY101100748T CY1110781T1 CY 1110781 T1 CY1110781 T1 CY 1110781T1 CY 20101100748 T CY20101100748 T CY 20101100748T CY 101100748 T CY101100748 T CY 101100748T CY 1110781 T1 CY1110781 T1 CY 1110781T1
Authority
CY
Cyprus
Prior art keywords
syndrome
prevention
treatment
pharmaceutical composition
systemic infection
Prior art date
Application number
CY20101100748T
Other languages
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
Life Sciences Research Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Sciences Research Partners Vzw filed Critical Life Sciences Research Partners Vzw
Publication of CY1110781T1 publication Critical patent/CY1110781T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ένας μερικός αναστολέας του παράγοντα VIII, όπως ένα μονοκλωνικό αντίσωμα είναι χρήσιμος για την πρόληψη και/ή τη θεραπευτική αγωγή μιας ασθένειας, που επιλέγεται από την ομάδα, που αποτελείται από το σύνδρομο συστημικής φλεγμονώδους απόκρισης, σήψη, σηπτικό σοκ, σχηματισμό θρόμβου στο μικροαγγειακό σύστημα και διάσπαρτη ενδοαγγειακή πήξη σε ένα θηλαστικό, δια μερικής αναστολής του σχηματισμού θρομβίνης.
CY20101100748T 2001-01-11 2010-08-10 Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης CY1110781T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26140501P 2001-01-11 2001-01-11
EP02447005A EP1222929B8 (en) 2001-01-11 2002-01-11 Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome

Publications (1)

Publication Number Publication Date
CY1110781T1 true CY1110781T1 (el) 2015-06-10

Family

ID=22993164

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100748T CY1110781T1 (el) 2001-01-11 2010-08-10 Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης

Country Status (7)

Country Link
EP (1) EP1222929B8 (el)
AT (1) ATE468136T1 (el)
CY (1) CY1110781T1 (el)
DE (1) DE60236386D1 (el)
DK (1) DK1222929T3 (el)
ES (1) ES2346189T3 (el)
PT (1) PT1222929E (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
JP4934796B2 (ja) * 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
US8119137B2 (en) 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
EP1910420B1 (en) * 2005-07-29 2011-05-18 Life Sciences Research Partners VZW Human inhibitory anti-factor viii antibodies binding to the a2 domain
CN102234641A (zh) * 2010-05-05 2011-11-09 杭州星博生物科技有限公司 一种快速获取特异性人源抗体可变区基因序列的方法
DE102013005184A1 (de) 2013-03-20 2014-09-25 fzmb GmbH, Forschungszentrum für Medizintechnik und Biotechnologie Verfahren zur Funktionalisierung einer Oberfläche

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
DE60033814T2 (de) * 1999-07-14 2007-11-08 D. Collen Research Foundation Vzw Monoklonaler Antikörper der Faktor VIII selbst in molarem Überschuß nur teilweise inaktiviert und eine Methode zur Herstellung solch eines Antikörpers

Also Published As

Publication number Publication date
EP1222929A2 (en) 2002-07-17
EP1222929B1 (en) 2010-05-19
ES2346189T3 (es) 2010-10-13
PT1222929E (pt) 2010-08-18
EP1222929A3 (en) 2002-09-18
DK1222929T3 (da) 2010-09-06
ATE468136T1 (de) 2010-06-15
EP1222929B8 (en) 2010-07-07
DE60236386D1 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
CY1110781T1 (el) Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
DE60122176D1 (de) Isoxazole und ihre verwendung als erk-inhibitoren
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200400022A1 (ru) Соединения и способы лечения или предупреждения инфекций flavivirus
ATE392421T1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
DE60118774D1 (de) Substituierte phenolderivate und deren salze als hemmstoffe von koagulations faktor x
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
ATE491701T1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
NO20033220L (no) Inhibitorer for cruzipain og andre cysteinproteaser
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DK2017265T3 (da) Kondenserede forbindelser, som inhiberer vanilje-receptor-subtype-1 (VR1)
ATE413388T1 (de) Muskarin antagonisten
ATE302017T1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
NO934218D0 (no) Inhibitorer av cathepsin G og elastase for forhindring avbindevevsnedbrytning
MA27308A1 (fr) Derives de n-( (3-oxo-2, 3-dihydro- 1h-isoindol-1-yl) acetyl)guanidine en tant qu'inhibiteurs du nhe-1-destines au traitement de l'infractus et de l'angine de poitrine
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
NO20022584D0 (no) Kombinerte midler for behandling av glaukom
SE0003476D0 (sv) Compounds
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.